natgillin/translations-raw huggingface dataset:
A recombinant retroviral particle comprising the vector of any of the preceding claims, wherein the vector is optionally for use in gene therapy, or a retroviral provirus produced by infection of target cells with the recombinant retroviral particle, or RNA or mRNA of the retroviral particle so produced. 
Rekombinantna retrovirusna čestica koja sadrži vektor prema bilo kojem od prethodnih patentnih zahtjeva, naznačena time što je vektor izborno za uporabu u genskoj terapiji, ili retrovirusni provirus proizveden pomoću infekcije ciljanih stanica rekombinantnom retrovirusnom česticom, ii RNA ili mRNA tako proizvedene Tetrovirusne čestice.
The aqueous formulation of item 6, wherein the analogue of exendin-4 is selected from a group comprising lixisentatide, exenatide and liraglutide. 
Vodena formulacija u skladu s patentnim zahtjevom 1, naznačena time što sadrži analog eksendina-4, kojeg se bira iz skupine koju čine liksisenatid, eksenatid i liraglutid.
Flavourings can include toffee flavouring QL17192, lemon oil, orange oil, and spearmint flavour 79020. 
Aromati mogu sadržavati aromat karamele QL17192, limunovo ulje, narančino ulje i aromu nane 79020.
The rAAV vector according to claim 7, wherein the rAAV vector is comprised within an AAV8 Y733F viral particle. 
TAAV vektor prema zahtjevu 7, naznačen time što se rAAV vektor nalazi unutar AAV8 Y733F virusne čestice.
A compound of Formula (I) according to claims 1 or 2 wherein both R1 and R2 are hydrogen or one is hydrogen and the other is methyl or trifluoromethyl. 
Spoj formule (I) prema patentnim zahtjevima 1 ili 2 naznačeno time da oba R' i R jesu vodik ili jedan jest vodik a drugi je metil, etil, propil, fert-butil, koji može biti supstituiran s hidroksi ili fluorom, C3-Cg cikloalkil, koji može biti supstituiran s hidroksi ili fluorom.
The mixture was stirred at room temperature over night. 
Smjesa se miješa na sobnoj temperaturi preko noči.
In some embodiments, the cardiovascular condition is selected from the group consisting of acute coronary syndrome, peripheral arterial disease, thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failure, myocardial infarction, glomerulonephritis, thrombotic stroke, thromboembolic stroke, and cerebral ischemia. 
Spoj za uporabu prema zahtjevu 9 gdje se to kardiovaskularno stanje izabire iz grupe koja obuhvaća akutni koronarni sindrom, perifernu arterijsku bolest, trombozu, aterosklerozu, restenozu, hipertenziju, anginu pektoris, aritmiju, zatajenje srca, infarkt miokarda, glomerulonefritis, trombotski moždani udar, tromboembolijski moždani udar i cerebralnu ishemiju.
determining at least one transformation unit which is split from the coding unit using information about division for a transformation unit, wherein the information about division for the transformation unit is parsed from the bitstream; 
Uređaj (500, 1500) za dekodiranje slike, te uređaj sadrži: entropijski dekoder (520, 1510) koji provodi entropijsko dekodiranje za dobivanje kvantiziranih transformacijskih koeficijenata najmanje jedne transformacijske jedinice (870) u kodirajućoj jedinici (810);
means for comparing a sequence of received symbols (ak') of each packet with a corresponding sequence of expected symbols (ak) for the same packet; and 
- = sredstvo za uspoređivanje sekvence zaprimljenih simbola (a;') svakog paketa s odgovarajućom sekvencom očekivanog simbola (a,) istog paketa; i
The antibody for use as claimed in claim 3, in which the antibody is a monoclonal, chimeric or humanized antibody, or is a fragment of an antibody, said fragment specifically binding to the tumor-associated antigen according to claim 3. 
Farmaceutski pripravak radi primjene sukladno bilo kojem od zahtjeva 1 do 3, pri čemu je protutijelo monoklonalno, kimerno ili humanizirano protutijelo ili fragment koji veže antigen protutijela.
Closing mechanism (1) for refrigerated display cabinets (2), according to any of the preceding claims, characterised in that the frontal displacement means comprise telescopic elements. 
Rashladna vitrina s mehanizmom za zatvaranje (1) u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što element za čeono pomicanje pomičnog odjeljka za zatvaranje (3) sadrži teleskopske elemente.
a compound selected from the group consisting of sulfonylureas, including their respective isomers a s well as their respective environmentally compatible salts or esters or amides or other derivatives; and 
A) spoj izabran iz grupe koja obuvaća sulfonamide, uključujući njihove odgovarajuće izomere kao i odgovarajuće, prihvatljive za okoliš, soli ili estere ili amide ili druge derivate; i
reacting the compound of formula IV to form the compound of formula I. 
reakcije spoja formule IV zbog formiranja spoja formule I.
Pressing is carried out on termination of the profiling stage, although it can be done during passage through the profiling rollers or after stretching but before profiling. 
Prešanje se izvodi na završetku postupka profiliranja, iako on može biti učinjen za vrijeme prolaza ktoz valjke za profiliranje ili nakon rastezanja, ali prije profiliranja.
Further ethanol (10 cm3) was added and the solution heated at 75°C for 3 hours and cooled to room temperature. 
Dodano je još etanola (10 cm?) i otopina je zagrijavana na 75% C tijekom 3 sata i ohlađena na sobnu temperaturu.
These bacteria are capable of colonising the intestinal tract, more specifically the colon, where they exert beneficial effects on human health. 
Te bakterije mogu naseliti probavni sustav, preciznije debelo crijevo, gdje povoljno utječu na čovjekovo zdravlje.
The method of claim 1, wherein the sugar moieties of the oligonucleotide backbone are replaced with non-natural moieties. 
Antisens oligonukleotid u skladu sa zahtjevom 3, naznačen time što šećerni ostaci u oligonukleotidnoj okosnici su zamijenjeni neprirodnim ostacima.
In a preferred embodiment the container provided with the base unit is temporarily kept apart from the base part by means of resilient means until an increased downwards force is applied to the container whereby the container moves downwards causing the piercer to pierce the sealed outlet. 
U izvedbi kojoj se daje prednost spremnik ima osnovnu jedinicu koju se privremeno drži podalje od osnovnog dijela pomoću elastičnog sredstva, sve dok se na spremnik ne primijeni povećana sila usmjerena prema dolje, čime se spremnik pomakne prema dolje i time se uzrokuje da bušilo probije začepljen izlaz.
The antagonist of claim 3, wherein said soluble ActRIIa polypeptide comprises an amino acid sequence that is at least 90% identical to SEQ ID NO:2 or SEQ ID NO:3. 
aminokiselinska sekvenca SEQ ID NO: 3 ili aminokiselinska sekvenca koja je najmanje 90% ili 95% identična sa SEQ ID NO: 3;
The rodent of claim 1, wherein the human portion of the chimeric human/rodent MHC II a polypeptide is encoded by a HLA class II a chain gene selected from the group consisting of an HLA-DR a chain gene, an HLA-DQ a chain gene, and an HLA-DP a chain gene and/or the human portion of the chimeric human/rodent MHC II B polypeptide is encoded by a human HLA class II gene selected from the group consisting of an HLA-DR B chain gene, an HLA-DQ B chain gene, and an HLA-DP B chain gene. 
Postupak prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da se ljudski dio kimernog ljudskog/glodarskog MHC II-a-polipeptida kodira putem HLA-razreda II-gena a-lanca odabranog iz skupine koja se sastoji od HLA-DR-gena a-lanca, HLA-DQ-gena a-lanca i HLA-DP-gena a-lanca i/ili se ljudski dio kimernog ljudskog/glodarskog MHC II-a-polipeptida kodira putem HLA-razreda II-gena odabranog iz skupine koja se sastoji od HLA-DR-gena B-lanca, HLA-DQ-gena B-lanca i HLA-DP-gena B-lanca, prema potrebi, s time da HLA-DR-geni a-lanca i B-lanca su HLA-DR4-geni a-lanca odnosno B-lanca.
In the embodiment shown in Figure 2, the short fuel element 10 is a pressed carbon rod or plug, about 20 mm long, which is provided with an axial hole 16. 
U realizaciji koja je prikazana na SI. 2, kratki gorivi element 10 je prešan ugljični štap ili čep, dužine oko 20 mm, koji je osiguran sa aksijalnim otvorom 16.
The method of claim 1 wherein said selective sequencing comprises the use of a sequencing array. 
Postupak prema zahtjevu 1, naznačen time da navedeno sekvenciranje sadrži upotrebu sekvencirajućeg niza.
Schematically, the heat transfer process is as follows: as the solar radiation (1) strikes the receiver (2) surface, thus heat is transferred by conduction along the upper layer (5). 
Prijamnik (2) sunčevog zračenja (1) prema bilo kojem od zahtjeva 1 do 5 naznačen time što prijamnik (2) ima oblik geometrije pola šupljeg polihedrona.
A polypeptide for use as a medicament for regenerating nerve fibers in a subject that has suffered a brachial plexus injury, wherein the polypeptide comprises an amino acid sequence that is at least 80% identical to amino acids 15-113 of SEQ ID NO:1, and wherein the polypeptide, when dimerized, binds to a complex containing GFRa3 and RET. 
Polipeptid za uporabu u vidu lijeka za regeneriranje živčanih vlakana kod subjekta koji je pretrpio povredu brahijalnog pleksusa, naznačen time, što polipeptid sadrži aminokiselinsku sekvencu koja je najmanje 80% identična sa amino-kiselinama 15-113 SEQ ID NO:1, i gdje se polipeptid, kada se dimerizira, vezuje u kompleks koji sadrži GFR93 1 RET.
Here a significant amount means an amount sufficient to detectably improve the light stability of the beverage or foodstuff. 
Ovdje značajna količina znači količinu dovoljnu da se mjerljivo poboljša stabilnost na svjetlo pića ili hrane.
A pharmaceutical composition as in clause 1 is used for the treatment of traveler's diarrhea caused by E . coli. 
Oralni farmaceutski pripravak s kontroliranim oslobađanjem u skladu sa zahtjevom 1, naznačen time da je za uporabu u liječenju putnih proljeva kojima je uzročnik E. coli.
Then addition of a solution of 3.6 sulfuric acid in 57 ml water, extraction with 70 ml ethyl acetate, washing with water, saturated brine, 5% sodium hydrogencarbonate, 25% brine, drying over MgSO4 and evaporation. 
Zatim slijedi dodavanje otopine 3,6 sumporne kiseline u 57 ml vode, ekstrakcija sa 70 ml etil acetata, ispiranje vodom, zasićenom otopinom soli, 5% natrij hidrogenkarbonatom, 25% otopinom soli, sušenje iznad MgS04 i evaporacija.
In this reaction displacement of the halogeno leaving group Lg results in the formation of the acid HLg in-situ and auto-catalysis of the reaction. 
U ovoj reakciji, zamjena halogeno izlazne skupine rezultira auto-katalitičkim #n-situ nastankom kiseline.
The compound of claim 7, Y is selected from the group consisting of: 
Spoj u skladu s patentnim zahtjevom 7, naznačen time što Y se bira iz skupine koju čine:
at least one nucleotide sequence for at least one activation sequence for the expression of one or more of components (I) to (III), wherein said activation sequence can be activated in the microorganism and/or is tissue cell-specific, tumor cell-specific, macrophage-specific, dendrite-specific, lymphocyte-specific, function-specific or non-cell-specific; 
najmanje jedan nukleotidni odsječak najmanje jednog aktivacijskog odsječka za eksprimiranje jednog ili više sastavnih dijelova (I) do (III), pri čemu se navedeni aktivacijski odsječak može aktivirati u mikroorganizmu i/ili je specifičan za stanice tkiva, stanice tumora, makrofaga, dendrita, limfocita, funkcijski specifičan ili nespecifičan u odnosu na stanice;
in the presence of a coupling reagent, such as o-benzotriazol-1-yl-N,N,N′,N′-tetramethyluronium tetrafluoroborate (TBTU) to the corresponding amide, i.e. the compound of Formula I. The reaction can be carried out in an inert solvent, such as dimethyl formamide (DM), methylenchloride and acetonitrile, or mixture thereof, under standard conditions. 
H >, i iv u prisutnosti reagensa za spajanje, poput o-benzotriazol-1-1l-N,N,N\N'-tetrametiluronij tetrafluoroborata (TBTU) do odgovarajućeg amida, spoja s formulom I. Reakcija se može provoditi u inertnom otapalu, poput dimetil formamida (DMEF), metilenklorida i acetonitrila ili njihove mješavine, pod uobičajenim uvjetima.
The transformation can be performed by any known method per se. Preferably, the transformant of the present invention is either a host cell transformed with an expression vector comprising a polynucleotide comprising a sequence encoding the heavy-chain variable region of the Fab′ fragment of the present invention and a polynucleotide comprising a sequence encoding the light-chain variable region of the Fab′ fragment, or a host cell transformed with an expression vector comprising a polynucleotide comprising a sequence encoding the heavy-chain variable region of the Fab′ fragment of the present invention and an expression vector comprising a polynucleotide comprising a sequence encoding the light-chain variable region of the Fab′ fragment. 
(a) stanica domaćin transformirana ekspresijskim vektorom koji sadrži polinukleotid koji sadrži slijed koji kodira teškolančani fragment Fab* fragmenta u skladu s patentnim zahtjevom 1 i polinukleotid koji sadrži slijed koji kodira laki lanac Fab' fragmenta u skladu s patentnim zahtjevom 1; 1 (b) stanica domaćin transformirana ekspresijskim vektorom koji sadrži polinukleotid koji sadrži slijed koji kodira teškolančani fragment Fab' fragmenta u skladu s patentnim zahtjevom 1 i ekspresijskim vektorom koji sadrži polinukleotid koji sadrži slijed koji kodira laki lanac Fab' fragmenta u skladu s patentnim zahtjevom 1,1 konjugiranju Fab* fragmenta protutijela protiv ljudskog NGF s polietilen-glikolom.
An adjuster nut is threaded onto the end of the protruding threaded portion. 
Navrtka za podešavanje je postavljena na kraj dijela s navojem koji strši.
providing a vial having a mouth opening closed by a closure as claimed in any one of claims 1 to 18, passing a hollow needle through the closure, introducing the substance into the vial via the needle, withdrawing the needle from the vial and closure, and sealing the residual puncture hole in the closure by heat sealing. 
Postupak za uvođenje tvari u bočicu, naznačen time, što ima sljedeće korake: dobavljanje bočice koja ima ulazni otvor zatvoren zatvaračem kao što je navedeno u bilo kojem od pateninih zahtjeva 1 do 18, provođenje šuplje igle kroz zatvarač, uvođenje tvari u bočicu kroz navedenu iglu, izvlačenje navedene igle iz bočice i iz zatvarača, i nepropusno zatvaranje preostale probušene rupice u zatvaraču pomoću vrućeg nepropusnog zatvaranja.
Method according to the preceding claim, characterised in that the shaping is performed by the air-gap spinning method, wherein the air gap being preferably at least 10 mm, preferably at least 20 mm and at most 500 mm. 
Metoda prema nekom od gore navedenih zahtjeva, naznačena time da je oblikovanje provedeno metodom okretanja zračnog raspora pri čemu je zračni raspor preporučljivo barem 10 mm i 20 mm te najviše 500 mm.
d is an integer selected from 0 to 1; 
je d je prirodni broj od 0 do 1;
an ischemic heart condition, preferably stable angina, unstable angina, or vasospastic angina, 
(a) ishemijskog stanja srca, poželjno stabilna angina, nestabilna angina, ili vazospastična angina,
treating the reaction mixture prepared in Step (f) with an acid in the presence of a solvent to form a corresponding salt; 
(g) tretiranje reakcijske smjese pripremljene u koraku (f) s kiselinom u prisutnosti otapala da bi se formirala odgovarajuća sol;
The conjugate according to claim 8, wherein the reactive functional groups are an aldehyde group, a maleimide group, a succinimide derivative, or combinations thereof. 
Konjugat prema zahtjevu 12, naznačen time da je reaktivna skupina odabrana iz aldehidne skupine, propionaldehidne skupine, butiraldehidne skupine, maleimidne skupine ili derivata sukcinimida.
Amino Acid Synonymous Group 
Aminokiselina Sinonimna skupina
The compound according to any of claims 1 to 12 for use in the treatment and/or prophylaxis of disorders and/or diseases selected from the group consisting of acute pain, chronic pain, neuropathic pain, muscular pain, visceral pain and inflammatory pain. 
Spoj prema bilo kojem od patentnih zahtjeva 1 do 12 naznačen time da je za uporabu za liječenje i/ili profilaksu poremećaja i/ili bolesti odabranih iz skupine koju čine akutna bol, kronična bol, neuropatska bol, bol u mišićima, visceralna bol i upalna bol.
a step of amidating the compound of the formula (3) by reacting with 2-aminoethanol (2). (in the formula, Me represents methyl and R1 represents a linear or branched C1-6 alkyl). 
[image] (u formuli Me predstavlja metil i R1 predstavlja nerazgranati ili razgranati C1-6alkil).
A composition comprising degarelix for use in the treatment of locally advanced prostate cancer in a subject, the treatment having a reduced incidence and/or likelihood of cardiac disorder in the treated subject. 
Pripravak koji sadrži degareliks za uporabo u liječenju metastatskog stadija raka prostate u subjektu koji ima osnovnu razinu seruma alkalne fosfataze (S-ALP) od 200 IU/L ili više (prije liječenja).
Compound of the following general formula (1): 
Spoj sljedeće opće formule (1):
The assembled product as claimed in claim 1, wherein the third element is provided with a dismantling groove or recess, said dismantling groove being adapted for insertion of a dismantling tool. 
Sastavljeni proizvod prema bilo kojem od prethodnih zahtjeva, naznačen time što je treći element opremljen sa žlijebom za rasklapanje (33) ili udubljenjem (34), pri čemu je navedeni žlijeb za rasklapanje prilagođen za umetanje alata za rastavljanje.
protonating the dissolved free base with hydrochloric acid; and allowing crystalline form I to form by cooling the dissolved protonated free base (e.g., at a temperature below 30°C). 
protoniranje otopljene slobodne baze sa klorovodičnom kiselinom; te dopuštanje da se stvori kristalni oblik I hlađenjem otopljene protonirane slobodne baze (npr., pri temperaturi ispod 30°C).
The process of claim 3, wherein said secondary amine is selected from the group consisting of piperidine, pyrrolidine, piperazine, dialkylamines, and diarylalkylamines. 
Postupak u skladu s patentnim zahtjevom 14, naznačen time što navedeni sekundarni amin se bira iz skupine koju čine piperidin, pirolidin, piperazin, dialkilamini i diarilalkilamini.
The reaction mixture was refluxed for 16 hours. 
Reakcijsku smjesu refluksira se 16 sati.
Other charged groups are available. 
Dostupnc su i drugc nabijene skupine.
A pharmaceutically acceptable liquid formulation having a pH of about 9.1 to 9.8 at 25° C., comprising about 2.5% to about 7% by weight levodopa, about 0.5% to about 2% by weight carbidopa, about 5% to about 18% by weight arginine, and about 0.25% to about 3% by weight ascorbic acid or a pharmaceutically acceptable salt thereof. A pharmaceutically acceptable liquid composition having a pH of about 9.1 to 9.8 at 25° C., comprising about 5% to about 10% by weight levodopa, about 0.5% to about 2% by weight carbidopa, about 10% to about 20% by weight arginine, about 0.5% to about 1% by weight ascorbic acid, and an agent that inhibits the formation of oxidation products selected from the group consisting of L-cysteine and N-acetyl cysteine, 
(iv) 5.4% masenog udjela levodopa, 1,5% masenog udjela karbidopa, 1% masenog udjela askorbrinske kiseline ili natrijevog askorbata, i 12,3%, 13,5% ili 14,8% masenog udjela arginina; ili (v) 7% masenog udjela levodopa, 2% masenog udjela karbidopa, 1% masenog udjela askorbinske kiseline ili natrijevog askorbata, i 17,6% masenog udjela arginina. Farmaceutski prihvatljiv tekući sastav iz bilo kojeg zahtjeva 1 do 6, formuliran za kontinuiranu subkutanu, transdermalnu, intrađuodenalnu ili intravenoznu primjenu. Farmaceutski prihvatljiv tekući sastav iz bilo kojeg zahtjeva 1 do 7, za upotrebu u liječenju neuroloških poremećaja ili poremećaja pokreta poput Parkinsonove bolesti.
The composition or aerosol of any of claims 6 to 9, wherein the solution has a concentration of levofloxacin or ofloxacin greater than about 10 mg/ml, preferably greater than about 25 mg/ml, more preferred greater than about 35 mg/ml, even more preferred greather than about 40 mg/ml, highly preferred greater than about 50 mg/ml, and most preferred of 100 mg/ml. 
10. Smjesa ili aerosol iz bilo kojeg od patentnih zahtjeva 6 do 9, pri čemu ovaj rastvor ima koncentraciju levofloksacina ili ofloksacina veću od oko 10 mg/ml, preporučljivo veću od oko 25 mg/ml, još preporučljivije veću od oko 35 mg/ml, još preporučljivije veću od oko 40 mg/ml, izrazito preporučljivije veću od oko 50 mg/ml, i najpreporučljivije od 100 mg/ml.
A method as in claim 8 wherein the disorder caused by dysfunctions of voltage gated sodium and/or calcium channels is selected from neuropathic pain, chronic pain, acute pain, headaches, neurological conditions, neurogenerative disorders, cognitive disorders, psychiatric disorders, vertigo, tinnitus, muscle spasm, cardiovascular diseases, endocrine disorders involving excessive or hypersecretory or otherwise inappropriate cellular secretion of an endogenous substance, liver diseases, inflammatory processes affecting all body systems, disorders of the gastrointestinal (GI) tract, disorders of the genito-urinary tract, ophthalmic diseases and eating disorders. 
10. Spoj iz patentnog zahtjeva 9, naznačen time da je poremećaj uzrokovan disfunkcijama natrijevih i/ili kalcijevih kanala ovisnih o naponu odabran od sljedećih: neuropatska bol, kronična bol, aktuna bol, glavobolje, neurološka stanja, neurodegenerativni poremećaji, kognitivni poremećaji, psihijatrijski poremećaji, vrtogalvica, tinitus, mišićni spazam, kardiovaskularne bolesti, endokrini poremećaji koji obuhvaćaju prekomjerno ili hipersekrecijsko ili na drugi način neodgovarajuće stanično izlučivanje endogene tvari, bolesti jetre, upalni procesi koji djeluju na sve tjelesne sustave, poremećaji gastrointestinalnog trakta, poremećaji genito-urinarnog trakta, bolesti oka i poremećaji prehrane.
each independently represents an unsubstituted or substituted C1-8 alkyl group, an unsubstituted or substituted C2-8 alkenyl group, an unsubstituted or substituted C2-8 alkynyl group, an unsubstituted or substituted C3-8 cycloalkyl group, an unsubstituted or substituted C4-8 cycloalkenyl group, an unsubstituted or substituted C6-10 aryl group, an unsubstituted or substituted heterocyclic group, an unsubstituted or substituted C1-8 acyl group, an unsubstituted or substituted (1-imino)C1-8 alkyl group, an unsubstituted or substituted carboxyl group, an unsubstituted or substituted carbamoyl group, an unsubstituted or substituted hydroxyl group, an unsubstituted or substituted amino group, an unsubstituted or substituted mercapto group, a substituted sulfonyl group, a halogeno group, a cyno group, or a nitro group; 
svaki neovisno predstavlja nesupstituiranu ili supstituiranu skupinu C1-8 alkil, nesupstituiranu ili supstituiranu skupinu C2-8 alkenil, nesupstituiranu ili supstituiranu skupinu C2-8 alkinil, nesupstituiranu ili supstituiranu skupinu C3-8 cikloalkil, nesupstituiranu ili supstituiranu skupinu C4-8 cikloalkenil, nesupstituiranu ili supstituiranu skupinu C6-10 aril, nesupstituiranu ili supstituiranu heterocikličku skupinu, nesupstituiranu ili supstituiranu skupinu C1-8 acil, nesupstituiranu ili supstituiranu skupinu (1-imino)C1-8 alkil, nesupstituiranu ili supstituiranu karboksilnu skupinu, nesupstituiranu ili supstituiranu karbamoil skupinu, nesupstituiranu ili supstituiranu hidroksilnu skupinu, nesupstituiranu ili supstituiranu amino skupinu, nesupstituiranu ili supstituiranu merkapto skupinu, supstituiranu sulfonil skupinu, halogenu skupinu, cijano skupinu, ili nitro skupinu;